mofezolac has been researched along with Ovarian Neoplasms in 1 studies
mofezolac: Cyclooxygenase 1 inhibitor; structure in first source; RN from Toxlit
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ovarian cancer is among the highest mortality gynecological cancers." | 1.51 | Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection. ( Aleem, AM; Ferorelli, S; Fortuna, CG; Iaselli, MC; Marnett, LJ; Miciaccia, M; Pati, ML; Perrone, MG; Scilimati, A, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scilimati, A | 1 |
| Ferorelli, S | 1 |
| Iaselli, MC | 1 |
| Miciaccia, M | 1 |
| Pati, ML | 1 |
| Fortuna, CG | 1 |
| Aleem, AM | 1 |
| Marnett, LJ | 1 |
| Perrone, MG | 1 |
1 other study available for mofezolac and Ovarian Neoplasms
| Article | Year |
|---|---|
Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection.
Topics: Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Fem | 2019 |